Verona Pharma Plc (VRP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Verona Pharma Plc (VRP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10169
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company’s lead candidate, RPL554 is a bronchodilator/anti-inflammatory drug which is being developed for a wide range of indications including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma. The company has collaborations with King’s College London McGill University and The University of North Carolina for conducting research and experimental studies and to the fund exploratory studies. It has operations across North America and the UK. Verona Pharma is headquartered in London, the UK.

Verona Pharma Plc (VRP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Verona Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Verona Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 9
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Verona Pharma Enters into Agreement with European Technology Companies 11
Equity Offering 12
Verona Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 12
Verona Pharma Raises USD78 Million in Public Offering of Shares 13
Verona Pharma Announces Exercise of Over-Allotment Option for Public Offering of ADS for USD87.2 Million 14
Verona Pharma Raises USD2 Million in Private Placement of Shares 16
Verona Pharma Raises USD63 Million in Private Placement of Units 18
Verona Pharma Raises USD21.7 Million in Private Placement of Shares 21
Verona Pharma Completes Rights Offering Of Shares For US$1.7 Million 22
Verona Pharma Announces Private Placement Of Shares For US$1.3 Million 23
Verona Pharma Prices Private Placement Of Shares For US$2 Million 24
Verona Pharma Announces Private Placement Of Shares For US$8 Million 25
Verona Pharma Plc – Key Competitors 26
Verona Pharma Plc – Key Employees 27
Verona Pharma Plc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2018: Verona Pharma: Operational update and financial results for the three and nine months ended September 30, 2018 29
Aug 07, 2018: Verona Pharma: Operational update and financial results for the three and six months ended June 30, 2018 36
May 08, 2018: Verona Pharma Operational Update and Financial Results for the First Quarter Ended March 31, 2018 37
Feb 27, 2018: Verona Pharma Reports Operational Update and Financial Results for Full Year Ended December 31, 2017 41
Nov 07, 2017: Verona Pharma Operational Update and Financial Results for the Third Quarter Ended September 30, 2017 48
Aug 08, 2017: Verona Pharma Interim Results for the Six Months Ended June 30, 2017 50
Feb 27, 2017: Verona Pharma Announces Financial results for the year ended 31 December 2016 51
Corporate Communications 53
Apr 11, 2018: Verona Pharma Announces Departure of Chief Medical Officer 53
Apr 03, 2017: Verona Pharma announces new collaborations to develop dry powder and MDI formulations for COPD 54
Apr 03, 2017: Verona Pharma Announces Board Change 55
Mar 31, 2017: Verona Pharma appoints commercial director 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Verona Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Verona Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Verona Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Verona Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 9
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Verona Pharma Enters into Agreement with European Technology Companies 11
Verona Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 12
Verona Pharma Raises USD78 Million in Public Offering of Shares 13
Verona Pharma Announces Exercise of Over-Allotment Option for Public Offering of ADS for USD87.2 Million 14
Verona Pharma Raises USD2 Million in Private Placement of Shares 16
Verona Pharma Raises USD63 Million in Private Placement of Units 18
Verona Pharma Raises USD21.7 Million in Private Placement of Shares 21
Verona Pharma Completes Rights Offering Of Shares For US$1.7 Million 22
Verona Pharma Announces Private Placement Of Shares For US$1.3 Million 23
Verona Pharma Prices Private Placement Of Shares For US$2 Million 24
Verona Pharma Announces Private Placement Of Shares For US$8 Million 25
Verona Pharma Plc, Key Competitors 26
Verona Pharma Plc, Key Employees 27
Verona Pharma Plc, Subsidiaries 28

List of Figures
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Verona Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Verona Pharma Plc (VRP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • KAZ Minerals PLC:企業のM&A・事業提携・投資動向
    KAZ Minerals PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's KAZ Minerals PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Tikcro Technologies Ltd (TIKRF):企業の財務・戦略的SWOT分析
    Summary Tikcro Technologies Ltd (Tikcro) is a biotechnology company that discovers, develops, manufactures and markets antibodies. The company undertakes clinical trials for its pipeline products PD1, PDL1, PDL2, TIGIT and CTLA-4 products, among others. Its products are based on 3D antigens designed …
  • Axelar AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Axelar AB (Axelar) is a drug development company that develops various novel anti-cancer treatments. The company lead drug candidateAXL1717 is used for the treatmentof non-small cell lung cancer. It also offers treatments for disease such as glioblastoma, sarcoma, malignant melanoma and mult …
  • Alstom SA (ALO):企業の財務・戦略的SWOT分析
    Alstom SA (ALO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Shopper’s Stop Ltd.:企業の戦略・SWOT・財務情報
    Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Calima Energy Ltd (CE1):石油・ガス:M&Aディール及び事業提携情報
    Summary Calima Energy Ltd (Calima Energy), formerly Azonto Petroleum Ltd is an oil and gas exploration and development company that invests in, acquires, explores, and produces oil and gas resources. The company provides acquisition, production, evaluation, exploration, development of oil and gas pr …
  • Power Mech Projects Ltd (POWERMECH):企業の財務・戦略的SWOT分析
    Power Mech Projects Ltd (POWERMECH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • AU Optronics Corp.:企業の戦略・SWOT・財務情報
    AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report Summary AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • WABCO Holdings Inc.:戦略・SWOT・企業財務分析
    WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Tomophase Corp:製品パイプライン分析
    Summary Tomophase Corp (Tomophase) is a medical device company that offers light-based imaging and therapy solutions. The company develops and commercializes opto-medical devices. It offers endoscopic tissue imaging system based on its proprietary technology optical coherence tomography. Tomophase's …
  • Schlumberger Ltd (SLB):石油・ガス:M&Aディール及び事業提携情報
    Summary Schlumberger Ltd (Schlumberger) is an oilfield services company that provides technology for reservoir characterization, drilling, production, and processing to the oil and gas industry. Schlumberger also supplies the industries with products and services, from exploration through production …
  • Gilead Sciences Inc (GILD):医療機器:M&Aディール及び事業提携情報
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency …
  • Omega Diagnostics Group Plc (ODX):企業の財務・戦略的SWOT分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company offers products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests fo …
  • Parexel International Corp:医療機器:M&Aディール及び事業提携情報
    Summary Parexel International Corp (Parexel) is a biopharmaceutical outsourcing service company which focuses on providing various services for managing the biopharmaceutical product lifecycle and for the development and commercialization of new medical therapies. It offers a comprehensive range of …
  • Greatcell Solar Ltd (GSL)-エネルギー分野:企業M&A・提携分析
    Summary Greatcell Solar Ltd (Greatcell Solar), formerly Dyesol Limited, is a renewable energy company that develops and commercializes Perovskite Solar Cells (PSC) or solid-state dye solar cell (DSC), the third generation photovoltaic technology. The company develops a range of PSC chemicals, compon …
  • Cyclopharm Ltd (CYC):医療機器:M&Aディール及び事業提携情報
    Summary Cyclopharm Ltd (Cyclopharm) is a radiopharmaceutical company that manufactures medical and healthcare equipment and components in the nuclear medicine business. The company’s products include Technegas, a lung imaging device used to diagnose the presence of blood clots in the lungs; and posi …
  • BJ’s Wholesale Club Inc:企業の戦略・SWOT・財務情報
    BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report Summary BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nabriva Therapeutics Plc (NBRV):製薬・医療:M&Aディール及び事業提携情報
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company’s product candidate includes lefamulin, a pleuromutilin antibiotic, being developed in both intravenous and oral formulations for the treatm …
  • Veniti Inc-医療機器分野:企業M&A・提携分析
    Summary Veniti Inc (Veniti) is a medical device company that develops venous system management solutions. The company manufactures, develops, and markets medical devices for the treatment of chronic venous diseases. It provides VICI venous stent system that is used to treat venous outflow obstructio …
  • Rexel S.A.:企業の戦略・SWOT・財務情報
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆